Updated:
H Tree Capital
H Tree Capital backs seed-stage founders where computation meets biology, fueling breakthroughs that transform how we live, age, and protect our planet.
H Tree Capital
H Tree Capital backs seed-stage founders where computation meets biology, fueling breakthroughs that transform how we live, age, and protect our planet. They focus on the intersection of computation and biology—backing founders from AI-driven drug discovery to enzyme-based carbon capture within human and planetary health. They invest globally in seed-stage companies as lead or co-lead and often commit to follow-on investments.
General information
Firm type
Private Equity
Year founded
2023
Location
Region
Europe
Country
United Kingdom
City
San Francisco
Corporate office
London, United Kingdom
Frequently asked questions
What is H Tree Capital's investment strategy?
H Tree Capital targets early-stage opportunities, spanning seed and general venture rounds. The firm describes itself as a private equity firm with a focus on company formation and early growth, though the specific sectors, check sizes, and geographies it prefers have not been publicly detailed. Without a published investment memorandum or portfolio, the strategy can only be characterized as generalist early-stage venture out of London.
Does H Tree Capital disclose its assets under management?
No. H Tree Capital has not publicly disclosed an AUM figure, fund sizes, or deployment totals. The firm does not appear in any major commercial databases with a verified asset number, and its own materials remain silent on capital raised or deployed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: